Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. billion and $812 million in 2028. The post Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine appeared first on Pharmaceutical Technology.
Let's personalize your content